Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Filings
36 filings of SUMICHEM since January 2025.
results 9, presentation 9, board outcome 9, transcript 4, dividend 3, credit rating 2
| Filed | Type | Subject | |
|---|---|---|---|
| 30 Oct 2026 | transcript Capex, Guidance, Management change, Results | Sumitomo Chemical India Limited has informed the Exchange about TranscriptAI summarySumitomo Chemical India filed the written transcript of its Q2 and H1 FY27 earnings call held on 27 October 2026. Management said Q2 FY27 revenue was INR 907 crore, down 2% year-on-year, and H1 FY27 revenue was INR 1,971 crore, down 1%; Q2 gross margin was 40.7% and EBITDA margin 20.5%. Management said H2 is expected to be challenging due to El Nino, low reservoir levels and uneven monsoon, and it aims to grow sales where the market allows while protecting profitability. Management said the Dahej greenfield project (about INR 150 crore) remains on track for commercial production in Q2 FY27-28, and inventory days rose to 115 from 95 a year earlier. Management said Mr. Suresh Ramachandran took charge as Managing Director on 1 September 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Oct 2026 | presentation Capex, Guidance, Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summarySumitomo Chemical India Ltd filed its investor presentation on financial results for the quarter and half-year ended 30 September 2026 (Q2FY27 and H1FY27). Q2FY27 revenue was Rs 907 crore, down 2% YoY; PAT was Rs 186 crore (down 15%); EBITDA was Rs 369 crore with a 20.5% margin (Q2FY26: 23.4%). H1FY27 revenue was Rs 1,971 crore, down 1% YoY; H1FY27 PAT was Rs 419 crore, down 4%. Management said weak monsoon and rainfall deficit hurt offtake, Q2 volumes fell by a high-single-digit percentage, and exports fell 23% to Rs 127 crore in Q2. Management said H2FY27 is expected to remain challenging, citing lower reservoir levels, extended El Nino impact and potential constraints on crop acreages; capex is progressing as planned. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Oct 2026 | results Results | Integrated Filing (Financial) for the quarter and half-year ended 30th September, 2026.AI summarySumitomo Chemical India Ltd filed its unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2026, along with related party transactions disclosure. Standalone revenue from operations for the quarter ended 30 September 2026 was ₹8,909.08 million, against ₹10,540.75 million in the quarter ended 30 June 2026 and ₹9,144.44 million in the quarter ended 30 September 2025. Standalone net profit for the quarter ended 30 September 2026 was ₹1,560.42 million, against ₹2,165.29 million in the preceding quarter and ₹1,778.97 million in the year-earlier quarter. Standalone revenue from operations for the half-year ended 30 September 2026 was ₹19,449.83 million, against ₹19,625.13 million in the half-year ended 30 September 2025; half-year net profit was ₹3,725.71 million, against ₹3,577.03 million. Basic and diluted EPS for the quarter ended 30 September 2026 was ₹3.13 per share (not annualised). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Oct 2026 | board outcome Dividend / buy-back, Results | Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the quarter and half-year ended 30th September, 2026.AI summarySumitomo Chemical India Ltd filed unaudited standalone financial results for the quarter and half-year ended 30 September 2026, approved by the Board at a meeting held on 26 October 2026 (meeting 3:23 PM to 3:30 PM), with Limited Review Reports from BSR & Co. LLP. Q2 FY27 standalone revenue from operations was ₹8,909.08 million, against ₹9,144.44 million in the quarter ended 30 September 2025, and profit for the period was ₹1,560.42 million (₹1,778.97 million a year earlier). Half-year standalone revenue from operations was ₹19,449.83 million (₹19,625.13 million in H1 FY26) and half-year profit for the period was ₹3,725.71 million (₹3,577.03 million). Basic and diluted EPS for the quarter was ₹3.13 (not annualised), and the half-year EPS was ₹7.46. Standalone cash flow statement shows dividend paid of ₹647.76 million in the half year ended 30 September 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jul 2026 | presentation Guidance, Management change, Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summarySumitomo Chemical India filed its investor presentation on results for the quarter ended 30 June 2026 (Q1FY27). Revenue rose 1% YoY to Rs 1,063 crore; EBITDA rose 6% to Rs 233 crore (margin 21.9%); reported PAT rose 20% to Rs 215 crore, including an exceptional insurance claim of Rs 26.9 crore. Management said the quarter was hit by delayed monsoon, lower kharif acreage and channel inventory corrections, while exports grew 26% YoY. Board reconstitution from 1 September 2026 is set out, including Dr. Suresh Ramachandran to be appointed Managing Director and Mr. Chetan Shantilal Shah's move to Non-Executive Non-Independent Director. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jul 2026 | results Results | Integrated Filing (Financial) for the quarter ended 30th June, 2026.AI summarySumitomo Chemical India Ltd filed unaudited standalone financial results for the quarter ended 30 June 2026, approved by the Board on 27 July 2026. Standalone revenue from operations for the quarter was ₹10,540.75 million, against ₹10,480.69 million in the quarter ended 30 June 2025. Standalone profit for the period was ₹2,165.29 million, against ₹1,798.06 million a year earlier; profit before tax after exceptional items was ₹2,912.61 million. Exceptional items included an insurance claim for business interruption of ₹268.96 million from the 2022-23 fire at the Bhavnagar plant. Basic and diluted EPS for the quarter was ₹4.34 (not annualised), against ₹3.60 a year earlier. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jul 2026 | board outcome Results | Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryBoard approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 at a meeting held 27 July 2026 (meeting 11:10 AM to 1:10 PM), with Auditors' Limited Review Reports attached. Standalone revenue from operations for Q1 FY27 was ₹10,540.75 million, against ₹10,480.69 million in the quarter ended 30 June 2025 and ₹6,714.91 million in the quarter ended 31 March 2026. Standalone profit for the period was ₹2,165.29 million, against ₹1,798.06 million a year earlier; this includes exceptional income of ₹268.96 million from an insurance business interruption claim relating to the 2022-23 Bhavnagar plant fire. Basic and diluted EPS (face value ₹10) was ₹4.34, against ₹3.60 in the year-ago quarter (not annualised). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Jun 2026 | transcript Capex, Dividend / buy-back, Guidance, Management change, Results | Sumitomo Chemical India Limited has informed the Exchange about TranscriptAI summarySumitomo Chemical India filed the written transcript of its Q4 and FY26 earnings call held on 28 May 2026. Management said FY26 PAT grew by more than 7% year-on-year to INR543 crores, with revenue up 3%, gross profit margin of 42%, EBITDA margin of 20.7% and net profit margin of 16.8%, all described as record levels. Management said Dr. Suresh Ramachandran is to be elevated to Managing Director from 1 September 2026, Chetan Shah is proposed as non-executive, non-independent director, and Sushil Marfatia retires from the Board on 31 August 2026, subject to AGM approval. Management said the company is debt-free with cash and liquid investments of about INR2,113 crores as on 31 March 2026, and net worth of INR3,394 crores, up 17% year-on-year. Management said it is cautiously optimistic on FY27, flagging rupee depreciation, rising input costs, a below-normal monsoon forecast (92% of long period average) and possible El Nino. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 May 2026 | presentation Guidance, Management change, Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summaryInvestor presentation on the financial results for the quarter and year ended 31 March 2026, filed under Regulation 30. Q4FY26 revenue Rs. 684 crore (up 1% YoY); Q4FY26 PAT Rs. 134 crore (up 12% YoY), PAT margin 19.6% (Q4FY25: 17.6%)... see note below. FY26 revenue Rs. 3,238 crore (up 3% YoY); FY26 PAT Rs. 543 crore (up 7% YoY), PAT margin 16.8%; one-time exceptional charge of Rs. 16.1 crore related to newly notified Labour Codes. Management said FY26 was challenging for the Indian agrochemical industry, but the company delivered its highest-ever profitability; it is cautiously optimistic for FY27, watching weather, El-Nino, raw material inflation and geopolitical developments. Board reconstitution effective 1 September 2026: Dr. Suresh Ramachandran proposed as Managing Director; Chetan Shantilal Shah to move to Non-Executive Non-Independent Director; Mukul Govindji Asher's term as Independent Director and Chairman ends 31 August 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 May 2026 | results Results | Integrated Filing (Financial) for the quarter and year ended 31st March, 2026.AI summarySumitomo Chemical India Ltd filed audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, with the board meeting held 4:04 PM to 4:46 PM on 26 May 2026. Standalone revenue from operations for FY2026 was ₹31,857.62 million, against ₹30,903.69 million in FY2025. Standalone net profit for FY2026 was ₹5,431.39 million, against ₹5,019.48 million in FY2025; basic and diluted EPS was ₹10.88 for FY2026 against ₹10.06 for FY2025. Standalone profit for the quarter ended 31 March 2026 was ₹1,106.10 million, against ₹984.07 million in the quarter ended 31 March 2025. The auditors' reports on standalone and consolidated results for FY2026 are unmodified, with no qualifications. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 May 2026 | dividend Dividend / buy-back | Sumitomo Chemical India Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 1.30 per equity share.AI summarySumitomo Chemical India Ltd filed on 26 May 2026 to inform exchanges that its Board, meeting on the same day, declared a dividend for FY 2025-26. The dividend is ₹1.30 per equity share on 49,91,45,736 equity shares of ₹10 each. The dividend is subject to approval by members at the Annual General Meeting and will be paid on or after 3 August 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 May 2026 | board outcome Dividend / buy-back, Results | Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summarySumitomo Chemical India Ltd filed its audited standalone and consolidated financial results for the year ended 31 March 2026, approved by the board on 26 May 2026. Standalone revenue from operations for FY2026 was ₹31,857.62 million, against ₹30,903.69 million in FY2025; profit for the year was ₹5,431.39 million, against ₹5,019.48 million. Standalone profit for the quarter ended 31 March 2026 was ₹1,106.10 million, against ₹984.07 million in the corresponding quarter of the prior year. The board declared a final dividend of ₹1.30 per equity share of ₹10 each for FY2026, on 49,91,45,736 equity shares. The board meeting ran from 4:04 PM to 4:46 PM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Apr 2026 | credit rating Rating | Sumitomo Chemical India Limited has informed the Exchange about Credit RatingAI summarySumitomo Chemical India Ltd filed an intimation under Regulation 30 of SEBI LODR dated 29 April 2026. CRISIL Limited has reaffirmed the credit rating on the company's bank loan facilities. Total bank loan facilities rated: ₹200 crore. Long-term rating reaffirmed at CRISIL AA/Stable. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2026 | presentation Capex, Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summaryRevised investor presentation for quarter and nine months ended 31 December 2025, filed to update the Additional Capex for Special Projects slide with estimated commercialization timelines (minor revision to the 27 January 2026 submission). Q3FY26 revenue from operations fell 12% YoY to Rs 537 crore (per the slide, Rs 642 crore was Q3FY25); Q3FY26 PAT was Rs 76 crore, down 13% YoY, including a one-time exceptional charge of about Rs 16 crore from the newly notified Labour Codes. 9MFY26 revenue rose 3% YoY to Rs 2,555 crore; 9MFY26 PAT rose 6% YoY to Rs 432 crore (adjusted for the exceptional item per the slide footnote). Management said the revenue decline reflected discontinuation of Animal Nutrition products distribution (about Rs 72 crore impact in the quarter), softer domestic agri-input demand and cautious distributor purchasing. Board-approved special projects include a herbicide intermediate plant at Dahej (capex about Rs 150 crore, commercialization Q2 FY2028-29) and fitment for two molecules at Tarapur (capex about Rs 10 crore, commercialization Q4 FY2027-28), both mainly for supply to the parent company. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jan 2026 | presentation Capex, Legal, Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summarySumitomo Chemical India filed its investor presentation on results for the quarter and nine months ended 31 December 2025 (Q3FY26 and 9MFY26). Q3FY26 revenue from operations was Rs 568 crore, down 12% YoY from Rs 642 crore; PAT was Rs 99 crore? No, PAT was Rs 76 crore (Q3FY25: Rs 87 crore), down 13% YoY including a one-time exceptional charge of about Rs 16 crore from newly notified Labour Codes. 9MFY26 revenue was Rs 2,555 crore, up 3% YoY from Rs 2,469 crore; 9MFY26 PAT was Rs 432 crore, up 6% YoY (9MFY25: Rs 407 crore). Management attributed the Q3 revenue decline to discontinuation of Animal Nutrition distribution in India (about Rs 72 crore impact), soft domestic agri-input demand and cautious distributor purchasing, while gross margin expanded 522 bps to 47.4% and EBITDA margin rose to 17.5%. The board approved about Rs 150 crore capex for a herbicide intermediate plant at Dahej and about Rs 10 crore for fitment at Tarapur, both to supply the parent company. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jan 2026 | results Results | Integrated Filing (Financial) for the quarter and nine months ended 31st December, 2025.AI summarySumitomo Chemical India Ltd filed its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, enclosed as Annexure I. The filing is an integrated filing under SEBI LODR Regulation 33; the cover letter itself does not state revenue, profit or other figures. Items B to E (proceeds deviation, debt default, related party transactions, audit qualification impact) are marked Not Applicable. The Board of Directors meeting that approved the results ran from 12:12 P.M. to 1:51 P.M. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jan 2026 | board outcome Results | Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summarySumitomo Chemical India Ltd filed its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025. The results were approved by the Board of Directors at its meeting held on 27 January 2026, which ran from 12:12 P.M. to 1:51 P.M. Limited review reports from the auditor M/s. BSR & Co. LLP are enclosed with the results. The filing does not state any revenue, profit or dividend figures in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Nov 2025 | transcript Capex, Guidance, Results | Sumitomo Chemical India Limited has informed the Exchange about TranscriptAI summarySumitomo Chemical India filed the written transcript of its Q2 and H1 FY26 earnings call held on 28 October 2025. Management said Q2 consolidated revenue was INR930 crores versus INR988 crores a year earlier, with the decline attributed to weather-driven volume contraction; Q2 PAT was INR178 crores versus INR193 crores. For H1 FY26, management reported revenue of INR1,987 crores (up 9% year-on-year), EBITDA of INR437 crores (22.0% margin) and PAT of INR356 crores (up 11%). Management said Excalia Max and Lentigo were launched pan-India, that it is too early to quantify their revenue, and that it is on target for them. Management expects a recovery in demand in the Rabi season and beyond, and cited export softness in Africa and Latin America in H1. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2025 | board outcome Results | Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summarySumitomo Chemical India Ltd filed its unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2025, along with related party transactions disclosure. Standalone revenue from operations for the quarter ended 30 September 2025 was ₹9,144.44 million, against ₹9,713.54 million a year earlier; profit for the period was ₹1,778.97 million (₹1,908.39 million a year earlier). For the half-year ended 30 September 2025, standalone revenue from operations was ₹19,625.13 million and profit for the period was ₹3,577.03 million, against ₹3,192.30 million in the half-year ended 30 September 2024. Basic and diluted EPS for the quarter was ₹3.56 (not annualised) per share of ₹10 face value, against ₹3.82 a year earlier. Board meeting commenced at 1:13 PM and concluded at 1:23 PM on 27 October 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2025 | presentation Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summarySumitomo Chemical India Limited filed its investor presentation on financial results for the quarter and half year ended 30 September 2025. Q2FY26 revenue was Rs 930 crore, down 6% from Rs 988 crore in Q2FY25; Q2FY26 PAT was Rs 178 crore against Rs 193 crore, down 8%. H1FY26 revenue was Rs 1,987 crore, up 9% from Rs 1,827 crore in H1FY25; H1FY26 PAT was Rs 356 crore against Rs 319 crore, up 11%. Management said the monsoon was strong overall but turned challenging during the key consumption period, causing missed spray cycles and lower volumes in Q2FY26, and expects improved rural sentiment and steady recovery in agri-input demand in H2FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2025 | results Results | Integrated Filing (Financial) for the quarter and half-year ended 30th September, 2025.AI summarySumitomo Chemical India Ltd filed its unaudited standalone and consolidated results for the quarter and half-year ended 30 September 2025, along with related party transactions disclosure. Standalone revenue from operations for Q2 FY26 was ₹9,144.44 million, against ₹10,480.69 million in the June 2025 quarter and ₹9,713.54 million in the September 2024 quarter. Standalone profit for the year (after tax) for the quarter was ₹1,778.97 million, against ₹1,908.39 million in the September 2024 quarter. Standalone revenue from operations for the half-year ended 30 September 2025 was ₹19,625.13 million, against ₹18,031.38 million in the corresponding period last year. Standalone basic and diluted EPS for the quarter was ₹3.56 (not annualised) and for the half-year ₹7.17. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2025 | board outcome Results | Sumitomo Chemical India Limited has informed the Exchange regarding Board meeting held on October 27, 2025 - Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended 30th September, 2025.AI summarySumitomo Chemical India Ltd filed its unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025, approved by the Board at a meeting held on 27 October 2025 (meeting ran from 1:13 PM to 1:23 PM). Standalone revenue from operations for the quarter ended 30 September 2025 was ₹9,144.44 million, against ₹9,713.54 million a year earlier; half-year revenue was ₹19,625.13 million versus ₹18,031.38 million. Standalone profit for the year (after tax) for the quarter was ₹1,778.97 million, against ₹1,908.39 million a year earlier; half-year profit was ₹3,577.03 million versus ₹3,192.30 million. Basic and diluted EPS for the half year was ₹7.17 per share (face value ₹10), against ₹6.39 a year earlier. Standalone paid-up equity share capital was ₹4,991.46 million; half-year dividend paid in cash flow was ₹598.05 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2025 | board outcome Results | Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summarySumitomo Chemical India Ltd filed its unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 (Annexure I, not included in the pages provided). The filing states the results were approved at a board meeting that ran from 12:01 P.M. to 12:35 P.M. on 4 August 2025. The company also stated that the related party transactions, default disclosure, deviation of proceeds and audit qualification impact formats are not applicable. The results are also available on the company website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2025 | presentation Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summarySumitomo Chemical India Ltd filed an investor presentation on its unaudited financial results for the quarter ended 30 June 2025 (Q1FY26). Q1FY26 revenue was Rs 1,057 crores versus Rs 839 crores in Q1FY25, up 26%. EBITDA was Rs 402 crores versus Rs 326 crores, up 23%, with EBITDA margin at 38.1% versus 38.9%; gross profit was Rs 219 crores versus Rs 161 crores, up 36%, with gross profit margin at 20.7% versus 19.2%. PAT was Rs 178 crores versus Rs 127 crores, up 41%, with net margin at 16.9% versus 15.1%. Management said domestic business grew 30% year on year and exports grew 7%, and cautioned that quarterly performance should be viewed in the context of seasonal variability. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2025 | results Results | Integrated Filing (Financial) for the quarter ended 30th June, 2025.AI summarySumitomo Chemical India Ltd filed its unaudited standalone and consolidated financial results for the quarter ended 30 June 2025, enclosed as Annexure I. The filing is an integrated filing under SEBI LODR Regulation 33, with the board meeting held from 12:01 P.M. to 12:35 P.M. The pages do not include the revenue, profit or other figures from the results. Other disclosures (public issue proceeds, loan defaults, related party transactions, audit qualifications) are marked Not Applicable. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2025 | board outcome Results | Sumitomo Chemical India Limited has informed the Exchange regarding Board meeting held on August 04, 2025.AI summaryBoard of Sumitomo Chemical India Ltd approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 at its meeting held on 4 August 2025. The results were reviewed earlier by the Audit Committee and come with Auditors' Limited Review Reports. The board meeting commenced at 12:01 P.M. and concluded at 12:35 P.M. The filing does not state revenue, profit or other figures. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Jun 2025 | transcript Capex, Guidance, Results | Sumitomo Chemical India Limited has informed the Exchange about TranscriptAI summaryFiled the written transcript dated 28 May 2025 of Sumitomo Chemical India's Q4 and FY'25 earnings call, held on 28 May 2025 (filed 3 June 2025). Management said FY'25 revenue grew 11% year-on-year, EBITDA grew 33% and PAT grew 37%, with EBITDA margin at 20.1% (up 339 bps) and net profit margin at 16.1% (up 308 bps). Management announced two Brownfield capex projects approved by the Board: about INR 55 crore at Bhavnagar to double capacity for an SCC molecule, and less than Rs. 10 crore at Tarapur for a newly launched global molecule, both expected to be completed in Q4 FY 2026-27. Management said it plans an initial investment of Rs. 300 crore for multiple Greenfield plants at Dahej. Consolidated Q4 FY'25 revenue was Rs. 679 crore (up 1% year-on-year) and EBITDA was Rs. 120 crore, against Rs. 140 crore a year earlier. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 May 2025 | presentation Capex, Guidance, Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summaryInvestor presentation on financial results for the quarter and year ended 31 March 2025 (Q4FY25 and FY25). FY25 revenue was Rs 3,149 crore, up 11% from Rs 2,844 crore in FY24; FY25 PAT was Rs 632 crore, up 33% from Rs 475 crore; FY25 EBITDA was Rs 1,290 crore, up 21%. Q4FY25 revenue was Rs 679 crore, up 1% from Q4FY24; Q4FY25 PAT was Rs 100 crore, down 9% from Q4FY24 (Rs 110 crore) per the presentation's Q4 figures. Management said FY25 was a year of solid recovery with about 10% adverse pricing impact in domestic and export markets, and expects normal monsoon and stable commodity prices to support FY26 demand. Management announced board-approved capex: a second plant at Bhavnagar for an SCC innovated product (approx. Rs 55 crore) and line modification at Tarapur (approx. Rs 10 crore), both targeted for completion in Q4FY27 (Jan-Mar 2027). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 May 2025 | results Dividend / buy-back, Results | Integrated Filing for the quarter and year ended 31.03.2025AI summarySumitomo Chemical India filed audited standalone and consolidated results for the quarter and year ended 31 March 2025, with auditors' reports unmodified. Standalone revenue from operations for FY2025 was ₹30,903.69 million (FY2024: ₹28,325.41 million); Q4 FY2025 revenue was ₹6,648.02 million. Standalone profit for the year was ₹5,019.48 million (FY2024: ₹3,696.74 million); Q4 FY2025 profit was ₹984.07 million. Standalone basic and diluted EPS for FY2025 was ₹10.06 (FY2024: ₹7.41); Q4 FY2025 EPS was ₹1.97 (not annualised). Standalone cash flow statement shows dividend paid of ₹440.28 million in FY2025 (FY2024: ₹3,098.16 million). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 May 2025 | dividend Dividend / buy-back | Sumitomo Chemical India Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2025, recommended Final Dividend of 1.20 per equity share.AI summarySumitomo Chemical India Ltd informed BSE and NSE that its Board met on 26 May 2025 and declared a dividend for FY 2024-25. The dividend is ₹1.20 per equity share on 49,91,45,736 equity shares of ₹10 each. The dividend is subject to approval by members at the Annual General Meeting and will be paid on or after 11 August 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 May 2025 | dividend Dividend / buy-back, Results | Sumitomo Chemical India Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2025, recommended Final Dividend of Rs. 1.20 per equity share.AI summarySumitomo Chemical India Ltd filed its audited standalone and consolidated financial results for the year ended 31 March 2025, approved by the Board on 26 May 2025. Standalone revenue from operations for FY2025 was ₹30,903.69 million, against ₹28,325.41 million in FY2024; standalone profit for the year was ₹5,019.48 million, against ₹3,696.74 million. Basic and diluted EPS for FY2025 was ₹10.06 (standalone), against ₹7.41 in FY2024. The Board declared a final dividend of ₹1.20 per equity share of ₹10 each for FY2025, on 49,91,45,736 equity shares. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 May 2025 | board outcome Dividend / buy-back, Results | Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.AI summaryBoard approved audited standalone and consolidated financial results for the year ended 31 March 2025 on 26 May 2025. Standalone revenue from operations for FY2025 was ₹ 30,903.69 million, up from ₹ 28,325.41 million in FY2024; standalone profit for the year was ₹ 5,019.48 million versus ₹ 3,696.74 million. Standalone profit before tax was ₹ 6,739.89 million for FY2025 compared with ₹ 5,033.47 million a year earlier. Board declared a dividend of ₹ 1.20 per equity share (face value ₹ 10) for the financial year ended 31 March 2025, on 49,91,45,736 equity shares. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Mar 2025 | results Legal, Results | Integrated (Financial)AI summarySumitomo Chemical India filed unaudited standalone results for the quarter and nine months ended 31 December 2024, approved by the Board on 27 January 2025, with a limited review report from BSR & Co. LLP. Q3 FY25 revenue from operations was ₹6,224.29 million versus ₹5,404.49 million in the year-ago quarter; Q3 profit after tax was ₹843.11 million versus ₹549.45 million. Nine-month revenue from operations was ₹24,255.67 million versus ₹21,681.71 million; nine-month profit after tax was ₹4,035.41 million versus ₹2,603.98 million. Basic and diluted EPS for the quarter was ₹1.69 (not annualised), and for the nine months ₹8.08 (not annualised). Notes state that the Government's October 2022 notification restricting glyphosate use to Pest Control Operators is not to be implemented until the Delhi High Court disposes of petitions challenging it. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Feb 2025 | credit rating Rating | Sumitomo Chemical India Limited has informed the Exchange about Credit RatingAI summarySumitomo Chemical India Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated 3 February 2025. CRISIL Limited has reaffirmed the credit rating on the Company's bank loan facilities. Total bank loan facilities rated: ₹ 200 Crore. Long-term rating: CRISIL AA/Stable. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jan 2025 | presentation Guidance, Results | Sumitomo Chemical India Limited has informed the Exchange about Investor PresentationAI summarySumitomo Chemical India Ltd filed an investor presentation on its financial results for the quarter and nine months ended 31 December 2024 (Q3FY25 and 9MFY25). Q3FY25 revenue was Rs 642 crore, up 18% from Rs 542 crore in Q3FY24; Q3FY25 PAT was Rs 106 crore, up 61% from Rs 66 crore, and gross margin was 42.1% versus 39.8%. 9MFY25 revenue was Rs 2,469 crore, up 14% from Rs 2,170 crore in 9MFY24; 9MFY25 PAT was Rs 407 crore, up 56% from Rs 260 crore. Management said export revenues grew 38% YoY in Q3FY25, with Latin America a standout, while farmer sentiment and prices were pressured by erratic rainfall, cyclones and lower commodity prices. Management said the company aims for steady growth in FY25-26, contingent on a normal monsoon. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Jan 2025 | results Results | Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summarySumitomo Chemical India Ltd filed unaudited standalone financial results for the quarter and nine months ended 31 December 2024, approved by the Board on 27 January 2025. Q3 FY25 (quarter ended 31 December 2024): revenue from operations ₹6,224.29 million, profit before tax ₹1,126.04 million, profit after tax ₹843.11 million, basic and diluted EPS ₹1.69 (not annualised), versus ₹5,404.49 million revenue and ₹549.45 million PAT in the quarter ended 31 December 2023. Nine months ended 31 December 2024: revenue from operations ₹24,255.67 million, profit after tax ₹4,035.41 million, EPS ₹8.08 (not annualised), versus ₹21,681.71 million revenue and ₹2,603.98 million PAT in the corresponding period last year. The notes state that the business is seasonal and depends on monsoon conditions, and that the Central Government's October 2022 notification restricting Glyphosate use to Pest Control Operators is under challenge in the Delhi High Court, with the Government's counsel stating it will not be implemented until the petitions are disposed of. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.